Timothy Wollaeger

Sanderling
San Diego, CA

Timothy Wollaeger has nearly thirty years' experience in the medical products and biotechnology fields in both corporate management and venture capital. Mr. Wollaeger joined Sanderling as a Managing Director in 2002, as head of the firm's San Diego office. Mr. Wollaeger began his career at Baxter International where his last position was Vice President and General Manager of the Company's operations in Mexico. In 1983 he joined Hybritech, Inc., San Diego's first biotechnology company, as Vice President and Chief Financial Officer. Following Hybritech's acquisition by Eli Lilly & Co in 1986, he became a founding General Partner of Biovest, a San Diego based venture capital firm. At Biovest, he helped found and remained an active Board member in Pyxis, Vical and Biosite. All three of these companies became public and Pyxis was acquired by Cardinal Health in 1996 for a $1 billion. He then helped found Columbia Hospital Corporation in 1990 and was a Senior Vice President and member of the Board of Directors until 1994, when he left to found the venture capital firm Kingsbury Capital Partners. Kingbury's investments include Aurora Biosciences, Amylin Pharmaceuticals, Phamis Software, Health Data Sciences, Senomyx, Sub-Q, TKT, Althea, and Digirad. In San Diego, he was named Entrepreneur of the Year in 1995 and Corporate Director of the Year in 2001. Mr. Wollaeger earned a B.A. in Economics from Yale in 1966, served as an officer in the U.S. Navy for three years, and earned an MBA from The Stanford Graduate School of Business in 1971.